Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun

Executive Summary

With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.

Advertisement

Related Content

UPDATED: Clear 'Yes' From Shareholders On Takeda/Shire Deal
Medical Aesthetics: A Untapped Pharma Market With Incoming Competition
Allergan's Botox Holds Its Own In Migraine, Despite CGRP Competition
Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
Sun Taps Mitsubishi For Ex-Novartis Japan Portfolio

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124289

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel